Zydus Wellness Ltd.
ZYDUSWELLFast Moving Consumer Goods filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
7 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 7 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20210802 | 2021-06-30 | yes | |
| TRANSCRIPT | 20211029 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220207 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220520 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220801 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221114 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230206 | 2022-12-31 | yes | |
| TRANSCRIPT | 20240807 | 2024-06-30 | yes | |
| TRANSCRIPT | 20240822 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241115 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250805 | 2025-06-30 | yes | |
| TRANSCRIPT | 20250814 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251114 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260522 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260810 | 2026-06-30 | yes | |
| TRANSCRIPT | 20260902 | 2026-06-30 | yes |
ZYDUSWELL
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 520.15 |
| 52-week range | 373.5 – 602.5 |
| Return 1M | -1.01% |
| Return 3M | 0.4% |
| Return 1Y | 7.09% |
| Return 3Y | 65.58% |
| Return 5Y | 10.57% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 1,437.00 |
| Other income | 4.00 |
| Total income | 1,441.00 |
| Cost of materials consumed | 308.00 |
| Purchases of stock-in-trade | 143.00 |
| Changes in inventories | 43.00 |
| Employee benefit expense | 97.00 |
| Finance costs | 26.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.70 | 0.00 |
| institutions foreign | 0.03 | 0.00 |
| institutions domestic | 0.19 | 0.00 |
| mutual funds | 0.19 | 0.00 |
| public | 0.30 | -0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 16 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 429.00 | 416.00 | 713.00 | 702.00 | 440.00 | 403.00 | 783.00 | 841.00 | 493.00 | 462.00 | 913.00 | 861.00 | 650.00 | 965.00 | 1,485.00 | 1,437.00 |
| Other income | 1.00 | 1.00 | 1.00 | 2.00 | 4.00 | 3.00 | 4.00 | 5.00 | 4.00 | 4.00 | 1.00 | 3.00 | 1.00 | 1.00 | 1.00 | 4.00 |
| Total income | 431.00 | 416.00 | 714.00 | 704.00 | 444.00 | 407.00 | 787.00 | 846.00 | 497.00 | 466.00 | 914.00 | 864.00 | 652.00 | 966.00 | 1,486.00 | 1,441.00 |
| Cost of materials consumed | 209.00 | 266.00 | 375.00 | 270.00 | 182.00 | 233.00 | 351.00 | 258.00 | 207.00 | 286.00 | 434.00 | 267.00 | 260.00 | 300.00 | 384.00 | 308.00 |
| Purchases of stock-in-trade | 14.00 | 15.00 | 53.00 | 36.00 | 14.00 | 11.00 | 52.00 | 55.00 | 13.00 | 7.00 | 68.00 | 51.00 | 44.00 | 129.00 | 192.00 | 143.00 |
| Changes in inventories | 21.00 | -48.00 | -77.00 | 27.00 | 46.00 | -35.00 | -48.00 | 61.00 | 37.00 | -58.00 | -91.00 | 69.00 | 2.00 | -76.00 | -57.00 | 43.00 |
| Employee benefit expense | 44.00 | 35.00 | 43.00 | 47.00 | 48.00 | 44.00 | 54.00 | 59.00 | 52.00 | 52.00 | 73.00 | 68.00 | 66.00 | 74.00 | 105.00 | 97.00 |
| Finance costs | 3.00 | 4.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 1.00 | 3.00 | 4.00 | 2.00 | 16.00 | 41.00 | 39.00 | 26.00 |
| Depreciation and amortisation | 6.00 | 6.00 | 7.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 13.00 | 11.00 | 25.00 | 56.00 | 55.00 | 57.00 |
| Other expenses | 126.00 | 119.00 | 174.00 | 205.00 | 134.00 | 137.00 | 212.00 | 253.00 | 164.00 | 159.00 | 238.00 | 249.00 | 255.00 | 477.00 | 590.00 | 605.00 |
| Total expenses | 423.00 | 397.00 | 580.00 | 597.00 | 435.00 | 403.00 | 632.00 | 694.00 | 479.00 | 456.00 | 740.00 | 719.00 | 668.00 | 1,001.00 | 1,309.00 | 1,279.00 |
| Profit before exceptional items and tax | 8.00 | 19.00 | 133.00 | 108.00 | 9.00 | 4.00 | 154.00 | 152.00 | 18.00 | 10.00 | 173.00 | 145.00 | -16.00 | -35.00 | 177.00 | 162.00 |
| Exceptional items | 0.00 | 0.00 | -7.00 | -14.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 0.00 | 0.00 | 0.00 | -34.00 | -7.00 | 0.00 | 0.00 |
| Profit before tax | 8.00 | 19.00 | 126.00 | 93.00 | 9.00 | 4.00 | 154.00 | 152.00 | 24.00 | 10.00 | 173.00 | 145.00 | -51.00 | -42.00 | 177.00 | 162.00 |
| Current tax | 0.00 | 0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 1.00 | 9.00 | 9.00 | 12.00 | 40.00 |
| Deferred tax | -0.00 | -0.00 | -19.00 | -17.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 2.00 | 17.00 | -7.00 | -11.00 | 4.00 | 3.00 |
| Tax expense | -0.00 | -0.00 | -19.00 | -17.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 2.00 | 17.00 | 2.00 | -2.00 | 15.00 | 43.00 |
| Profit for the period | 8.00 | 20.00 | 145.00 | 110.00 | 6.00 | 0.00 | 150.00 | 148.00 | 21.00 | 6.00 | 172.00 | 128.00 | -53.00 | -40.00 | 162.00 | 119.00 |
| Profit attributable to owners | 8.00 | 19.00 | 146.00 | 110.00 | 6.00 | 0.00 | 150.00 | 148.00 | 21.00 | 6.00 | 172.00 | 128.00 | -53.00 | -40.00 | 162.00 | 119.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | -0.00 | -0.00 | 0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.00 | 0.00 | -0.00 | -1.00 | 0.00 | -1.00 | -1.00 | -2.00 | -11.00 |
| Total comprehensive income | 8.00 | 19.00 | 146.00 | 110.00 | 6.00 | 0.00 | 150.00 | 148.00 | 21.00 | 6.00 | 171.00 | 128.00 | -54.00 | -41.00 | 160.00 | 108.00 |
| Earnings per share, basic | 1.33 | 3.07 | 22.84 | 17.35 | 0.93 | 0.05 | 23.62 | 23.21 | 3.28 | 1.01 | 27.01 | 20.10 | -1.66 | -1.25 | 5.09 | 3.74 |
| Earnings per share, diluted | 1.33 | 3.07 | 22.84 | 17.35 | 0.93 | 0.05 | 23.62 | 23.21 | 3.28 | 1.01 | 27.01 | 20.10 | -1.66 | -1.25 | 5.09 | 3.74 |
Annual results, as filed
| Line | 2018-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 503.00 | 1,767.00 | 1,867.00 | 2,009.00 | 2,255.00 | 2,328.00 | 2,709.00 | 3,961.00 |
| Other income | 35.00 | 11.00 | 9.00 | 10.00 | 5.00 | 14.00 | 14.00 | 6.00 |
| Total income | 538.00 | 1,778.00 | 1,876.00 | 2,020.00 | 2,260.00 | 2,342.00 | 2,722.00 | 3,967.00 |
| Cost of materials consumed | 151.00 | 754.00 | 744.00 | 885.00 | 1,100.00 | 1,036.00 | 1,184.00 | 1,212.00 |
| Purchases of stock-in-trade | 0.00 | 82.00 | 142.00 | 95.00 | 114.00 | 112.00 | 144.00 | 416.00 |
| Changes in inventories | 1.00 | -58.00 | -41.00 | 1.00 | -68.00 | -10.00 | -50.00 | -62.00 |
| Employee benefit expense | 57.00 | 175.00 | 164.00 | 164.00 | 167.00 | 193.00 | 237.00 | 313.00 |
| Finance costs | 2.00 | 140.00 | 84.00 | 26.00 | 16.00 | 24.00 | 12.00 | 98.00 |
| Depreciation and amortisation | 9.00 | 26.00 | 25.00 | 24.00 | 25.00 | 24.00 | 28.00 | 147.00 |
| Other expenses | 170.00 | 492.00 | 514.00 | 520.00 | 604.00 | 688.00 | 814.00 | 1,571.00 |
| Total expenses | 388.00 | 1,612.00 | 1,631.00 | 1,713.00 | 1,959.00 | 2,067.00 | 2,370.00 | 3,696.00 |
| Profit before exceptional items and tax | 150.00 | 165.00 | 244.00 | 306.00 | 301.00 | 274.00 | 353.00 | 271.00 |
| Exceptional items | 0.00 | -44.00 | -132.00 | 0.00 | -10.00 | -14.00 | 6.00 | -41.00 |
| Profit before tax | 150.00 | 121.00 | 112.00 | 306.00 | 291.00 | 260.00 | 359.00 | 230.00 |
| Current tax | 31.00 | -3.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 31.00 |
| Deferred tax | -17.00 | -18.00 | -7.00 | -3.00 | -19.00 | -7.00 | 12.00 | 3.00 |
| Tax expense | 13.00 | -20.00 | -7.00 | -3.00 | -20.00 | -7.00 | 12.00 | 33.00 |
| Profit for the period | 134.00 | 142.00 | 119.00 | 309.00 | 310.00 | 267.00 | 347.00 | 197.00 |
| Profit attributable to owners | 0.00 | 144.00 | 121.00 | 308.00 | 310.00 | 267.00 | 347.00 | 197.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 0.00 | 2.00 | 2.00 | -1.00 | 0.00 | -0.00 | -1.00 | -5.00 |
| Total comprehensive income | 134.00 | 144.00 | 121.00 | 308.00 | 310.00 | 267.00 | 346.00 | 193.00 |
| Earnings per share, basic | 34.27 | 24.58 | 19.55 | 48.54 | 48.78 | 41.94 | 54.52 | 6.20 |
| Earnings per share, diluted | 43.27 | 24.58 | 19.55 | 48.54 | 48.78 | 41.94 | 54.52 | 6.20 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 5,504.00 | 5,833.00 | 5,831.00 | 6,148.00 | 6,008.00 | 6,442.00 | 9,882.00 | 10,308.00 |
| Non-current assets | 4,887.00 | 4,925.00 | 4,940.00 | 4,898.00 | 4,898.00 | 5,338.00 | 8,714.00 | 8,941.00 |
| Current assets | 618.00 | 908.00 | 891.00 | 1,214.00 | 1,074.00 | 1,104.00 | 1,167.00 | 1,367.00 |
| Property, plant and equipment | 246.00 | 270.00 | 272.00 | 247.00 | 242.00 | 290.00 | 301.00 | 315.00 |
| Capital work-in-progress | 21.00 | 13.00 | 15.00 | 10.00 | 17.00 | 15.00 | 13.00 | 23.00 |
| Goodwill | 3,920.00 | 3,920.00 | 3,920.00 | 3,920.00 | 3,920.00 | 4,010.00 | 4,846.00 | 4,942.00 |
| Other intangible assets | 544.00 | 542.00 | 542.00 | 541.00 | 540.00 | 824.00 | 3,300.00 | 3,339.00 |
| Inventories | 316.00 | 457.00 | 366.00 | 468.00 | 351.00 | 518.00 | 612.00 | 764.00 |
| Trade receivables | 99.00 | 208.00 | 129.00 | 283.00 | 210.00 | 367.00 | 253.00 | 384.00 |
| Cash and cash equivalents | 83.00 | 37.00 | 35.00 | 80.00 | 21.00 | 67.00 | 121.00 | 111.00 |
| Total equity and liabilities | 5,504.00 | 5,833.00 | 5,831.00 | 6,148.00 | 6,008.00 | 6,442.00 | 9,882.00 | 10,308.00 |
| Equity | 4,958.00 | 5,123.00 | 5,207.00 | 5,358.00 | 5,494.00 | 5,672.00 | 5,706.00 | 5,826.00 |
| Equity share capital | 64.00 | 64.00 | 64.00 | 64.00 | 64.00 | 64.00 | 64.00 | 64.00 |
| Other equity | 4,894.00 | 5,059.00 | 5,143.00 | 5,294.00 | 5,431.00 | 5,608.00 | 5,642.00 | 5,762.00 |
| Total liabilities | 547.00 | 710.00 | 624.00 | 791.00 | 513.00 | 770.00 | 4,176.00 | 4,482.00 |
| Non-current liabilities | 19.00 | 18.00 | 18.00 | 22.00 | 22.00 | 25.00 | 3,565.00 | 3,753.00 |
| Current liabilities | 528.00 | 692.00 | 606.00 | 769.00 | 491.00 | 746.00 | 610.00 | 728.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,886.00 | 3,035.00 |
| Borrowings, current | 210.00 | 292.00 | 348.00 | 324.00 | 150.00 | 185.00 | 150.00 | 152.00 |
| Trade payables | 255.00 | 313.00 | 195.00 | 363.00 | 264.00 | 429.00 | 334.00 | 461.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 112.00 | 92.00 | 137.00 | 246.00 | 295.00 | 380.00 | 93.00 | 226.00 |
| Net cash from investing activities | -13.00 | -85.00 | -0.00 | -19.00 | -299.00 | -224.00 | -2,868.00 | -2,910.00 |
| Net cash from financing activities | -211.00 | -138.00 | 15.00 | -26.00 | -214.00 | -186.00 | 2,801.00 | 2,698.00 |
| Purchase of property, plant and equipment | 17.00 | 45.00 | 14.00 | 28.00 | 19.00 | 66.00 | 70.00 | 102.00 |
| Net increase in cash | -113.00 | -132.00 | 152.00 | 201.00 | -218.00 | -30.00 | 26.00 | 17.00 |
| con:CFO.BEFORE_TAX | 115.00 | 93.00 | 138.00 | 249.00 | 292.00 | 377.00 | 112.00 | 256.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 3.00 | 1.00 | 1.00 | 3.00 | -3.00 | -3.00 | 19.00 | 30.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,850.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 0.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 369.00 | 2,818.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 66.45 | 67.10 | 68.54 | 69.15 | 69.62 | 69.62 | 69.62 | 69.62 | 69.63 | 69.63 | 0.70 | 0.70 | 0.70 | 0.70 |
| Domestic institutions | 22.19 | 22.05 | 20.23 | 19.68 | 19.42 | 19.44 | 20.36 | 20.12 | 19.76 | 19.28 | 0.19 | 0.19 | 0.19 | 0.19 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 18.39 | 0.18 | 0.18 | 0.18 | 0.19 |
| Insurance companies | 1.92 | 1.29 | 1.22 | 1.04 | 1.00 | 0.86 | 0.86 | 0.90 | 0.80 | 0.80 | 0.01 | 0.00 | 0.00 | 0.00 |
| Foreign institutions | 3.87 | 3.23 | 3.42 | 3.25 | 3.26 | 3.29 | 3.37 | 3.37 | 3.29 | 3.25 | 0.03 | 0.03 | 0.03 | 0.03 |
| Government | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.00 |
| Public | 33.55 | 32.90 | 31.46 | 30.85 | 30.38 | 30.38 | 30.38 | 30.38 | 30.37 | 30.37 | 0.30 | 0.30 | 0.30 | 0.30 |
| Non-institutional | 7.50 | 7.62 | 7.81 | 7.92 | 7.71 | 7.65 | 6.66 | 6.89 | 7.31 | 7.83 | 0.08 | 0.09 | 0.08 | 0.08 |
| Shares outstanding | 63632144 | 63632144 | 63632144 | 63632144 | 63632144 | 63632144 | 63632144 | 63632144 | 63632144 | 63632144 | 318160720 | 318160720 | 318160720 | 318160720 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Zydus Wellness Products Limited | Subsidiary | Any other transaction, Interest received, Purchase o | 2,211,650,000.00 | 10 |
| Zydus Healthcare Limited | Fellow Subsidiary | Any other transaction, Interest paid, Purchase of go | 1,818,320,000.00 | 7 |
| Zydus Wellness International DMCC | Subsidiary | Any other transaction, Interest received, Sale of go | 273,680,000.00 | 12 |
| Zydus Lifesciences Limited | Holding Company | Any other transaction, Purchase of goods or services | 91,720,000.00 | 11 |
| Mr. Tarun Arora | Chief Executive Officer & Whol | Remuneration | 46,430,000.00 | 2 |
| Heinz India Private Limited Employee Provident Fund | Post Employment Benefits Plan | Any other transaction | 16,500,000.00 | 1 |
| Heinz India Private Limited Provident Fund | Post Employment Benefits Plan | Any other transaction | 10,680,000.00 | 1 |
| Mr. Umesh V. Parikh | Chief Financial Officer | Remuneration | 10,550,000.00 | 1 |
| Zydus Wellness Sikkim Employees Group Gratuity Scheme | Post Employment Benefits Plan | Any other transaction | 2,500,000.00 | 1 |
| Heinz India Private Limited Pension Fund | Post Employment Benefits Plan | Any other transaction | 2,000,000.00 | 1 |
| Mukesh M. Patel & Co. | Enterprises Significantly Influenc | Purchase of goods or services | 1,630,000.00 | 2 |
| Mr. Ganesh N. Nayak | Non-Executive Director | Any other transaction | 600,000.00 | 1 |
| Mr. Srivishnu Raju Nandayala | Independent Director | Any other transaction | 600,000.00 | 2 |
| Mr. Nandish Joshi | Company Secretary | Remuneration | 520,000.00 | 1 |
| Ms. Dharmishtaben N. Raval | Independent Director | Any other transaction | 500,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2023-02-06 | Q3FY23 | LIMITED, Wellness, ZYDUS WELLNESS LIMITED | Read the call |
| 2022-11-14 | Q2FY23 | LIMITED, Wellness, ZYDUS WELLNESS LIMITED, \Nellness | Read the call |
| 2022-08-01 | Q1FY23 | LIMITED, Wellness, ZYDUS WELLNESS LIMITED | Read the call |
| 2022-05-20 | Q4FY22 | LIMITED | Read the call |
| 2022-02-07 | Q3FY22 | LIMITED | Read the call |
| 2021-10-29 | Q2FY22 | LIMITED, ZYDUS WELLNESS LIMITED | Read the call |
| 2021-08-02 | Q1FY22 | (CORPORATE, CADILA, LIMITED, ZYDUS WELLNESS LIMITED | Read the call |
What they said about it, quarter by quarter
| Topic | Q1FY22 | Q1FY23 | Q2FY22 | Q2FY23 | Q3FY22 | Q3FY23 | Q4FY22 |
|---|---|---|---|---|---|---|---|
| Capex | — | — | — | — | — | — | Our consolidated CAPEX for the year was Rs. |
| Capital allocation | — | So, are we still on look out or we would like to actually settle down with what we have done so far on acquisition before we make a move or we are rea… | — | — | As we speak, we have completed three years of acquisition of Heinz India Private Limited. | — | So, in the second quarter of 2019, soon after acquisition, we had touched 5.0, we have seen share going up to 5.5 and 5.7 and coming back to 5.0. |
| Costs | 10 crore of saving in the next financial year because this year is working part and this happens over the next couple of quarters and expense of that … | — | At the same time, the company faced significant inflationary pressure in key raw materials and packaging materials as the result of which our gross ma… | So like which of the raw materials are usually imported here? | As the country and the FMCG industry is reeling under the impact of inflation in the prices of key raw materials and packing materials, the company co… | — | And what was our raw material inflation in FY22? |
| Debt and cash | 435 crore and net debt level is about Rs. | So, if I were to break down Complan, and I think it is very important for us, when we ourselves review this to deleverage the brand and from the space… | — | — | Hi Sharvil, Tarun, this is Nirman here, it is a real pleasure to talk to you guys after a long time, my question is regarding future strategy, so we h… | I wanted to understand what is the net debt as of December 31, 2022? | So, is it fair to assume that earlier we were negative working capital cycle company, so now 24 to 25 days of working capital positive and that would … |
| Demand | Even though we were ready to deal with the crisis at operations and logistics level, the country saw lockdowns and restrictions across global in most … | To narrate a few, on the Glucon-D front, as a market demand led by on-the-go consumers opened up, which was absent during the last two consecutive sum… | — | However, with our interventions in terms of sachets and pouches launched in key markets and some in the pipeline, which will help us participate in a … | We continue to support the online sales through the third wave as we have seen higher demand on these platforms. | So it has delayed our movement in that direction and we think now everything is sorted, we have seen our supplies because we had to change the third-p… | The rising developed inflation has impacted consumer sentiments and affected consumer demand. |
| Guidance | My second question was, on the internal guidance with respect to some of the launches’ extension, so would you be sharing something because as we see … | And sir, any margin guidance you would like to work with for FY '23? | So, considering that, should we expect your operating margins to reach close to 20% by over the next two years? | We expect revival in consumer demand on completion of normal monsoon and increased government spending. | I think what has happened for us is the inventory correction has been more than the other years, because this year we expected a normal season, but Ap… | We expect that better mix coupled with appropriate price increases will help us to mitigate the inflationary impact on business. | Sir, can we expect like gross margins to revert back to around 55-56% by the end of FY23? |
| Margin | EBITDA was up by 14.8% year-on-year to Rs. | July 29, 2022 It may still give me operating leverage, if I can achieve my double-digit growth as we have, and I think it is somewhat a time that shou… | EBITDA was up by 12.6% year-on-year to Rs.305 million. | EBITDA degrew by 46.8% year-on-year to INR 163 million. | EBITDA was down by 34.8% year-on-year to ₹ 323 Zydus Wellness Limited February 2, 2022 million. | EBITDA degrew by 12.7% year-on-year basis to Rs.282 million. | Our gross margin as percentage to net sales have sequentially improved by 265 basis points on the back of price increase and cost improvement measures… |
| Pricing | no, we have taken about a little higher than 2% price increase on our portfolio effectively for the last quarters that will reflect, we are also runni… | But by and large other than that, we have been very responsible in terms of price increases. | Largely it’s led by Nutralite we are obviously planning forward to take price increase across other portfolio but in the current quarters. | Have you taken the required price hikes or it will continue to impact us? | To mitigate the impact, the company has taken two rounds of price increases during the last two quarters, which will help the company improve gross ma… | We have taken another round of price increase across our portfolio by the end of third quarter. | Since the company commands reasonable pricing par for most of its brands, it has been able to take calibrated price increase over the last couple of q… |
| Revenue growth | We remain optim9istic about the growth of our business and brands going forward. | We continue to drive the growth of ImmunoVolt through the launch of a popular consumer variant of Kaccha Mango towards the end of first quarter. | With the improved consumer sentiments and strong on ground execution during the quarter, the business witnessed good momentum, as a result of which th… | On the Glucon-D front, we continue to drive the growth of the brand post a good summer season through media activations, TV campaign during the quarte… | During 3Q, our company posted a year-on-year growth of 2.3% on net sales. | The sugar substitute category has registered a flat growth of MAT level at MAT level. | During the quarter, the company has posted net sales growth of 5.7% which includes volume growth of 0.4%. |